Resapp technology now in clinical use in COVID-19 fight.

Following a one month trial at a federally funded COVID-19 respiratory clinic in Queensland, ResApp Health Limited's (ASX: RAP), ResAppDx-EU smartphone app has been put into clinical use.

Health Hub Doctors Morayfield was the first respiratory clinic established with federal government funding to take pressure off local hospitals by treating mild-moderate respiratory illnesses and assessing patients requiring COVID-19 testing.

ResAppDx-EU is being used by doctors at the clinic to triage patients who present with respiratory symptoms, helping identify illnesses such as lower respiratory tract infections, pneumonia, asthma exacerbations and COPD exacerbations, while reducing the need for physical contact during the intital assessment.

The clinic sees up to 300 patients per day and has 65 general practitioners on staff.

Does this means Resapp's technology can be used to detect COVID-19?

I caught up with CEO Tony Keating a short time ago.

DISCLAIMER AND IMPORTANT INFORMATION I own shares in Resapp at the time of writing this post. However I do not accept any payment from this or any other companies I cover. Nor is my interview or blog in any way a recommendation and should not be seen as a form of financial advice. Disruptive technology stocks should be considered very speculative, high-risk, and extremely volatile. There are significant risks inherent in developing new technologies that are not discussed here. You should always seek professional advice before considering any share purchase or sale. Please read our full disclaimer.